Courtesy of Victoria Peel Yates.
In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced pancreatic cancer.
New research may hold the key to fixing the genetic error responsible for Down syndrome.
Shigella bacteria are increasingly resisting all antibiotics that can easily treat them, a recent report shows.
Alexandra Frost